1. Borman P, Tuncay F, Köybaşi M, Ergun U, Inan L. Coexistence of ankylosing spondylitis and multiple sclerosis. Acta Neurol Belg. 2011; 111:340–343.
2. Mignarri A, Dotti MT, Battisti C, Vallone I, Federico A. Occurrence of ankylosing spondylitis and multiple sclerosis-like syndrome in a HLAB27 positive patient. Neurol Sci. 2009; 30:329–332.
Article
3. Zhao S, Zhou H, Peng X, Zhu J, Wang W, Kang H, et al. Optic neuritis with positive HLA-B27: characteristic phenotype in the Chinese population. J Neurol Sci. 2016; 362:100–105.
Article
4. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85:177–189.
Article
5. Heredia S, Aparicio M, Armengol E, Juanola X. Rituximab therapy for ankylosing spondylitis associated to demyelinating disease of the central nervous system. Joint Bone Spine. 2016; 83:105–106.
Article
6. Pillay N, Hunter T. Delayed evoked potentials in patients with ankylosing spondylitis. J Rheumatol. 1986; 13:137–141.
7. Kim HJ, Park HY, Kim E, Lee KS, Kim KK, Choi BO, et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica. Neurobiol Dis. 2010; 37:349–355.
Article
8. Lin Z, Bei JX, Shen M, Li Q, Liao Z, Zhang Y, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet. 2011; 44:73–77.
Article